Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 6NIH 2OTHER_GOV 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Endocrine 1

Conditions

Thyroid Neoplasms 2Thyroid Cancer, Papillary 1Neoplasm Metastasis 1Adenocarcinoma, Follicular 1

Interventions

Cyclophosphamide 388Specimen Handling 377Magnetic Resonance Spectroscopy 328Radiotherapy 306Biopsy 273Cisplatin 258Carboplatin 255Paclitaxel 235Doxorubicin 226Fluorouracil 200Etoposide 197Vincristine 183Bevacizumab 181Filgrastim 170Gemcitabine 163Leucovorin 149Cytarabine 144aldesleukin 141Taxes 127Docetaxel 122Chemotherapy, Adjuvant 114Oxaliplatin 113fludarabine phosphate 111Methotrexate 108Rituximab 107Radiation 106Bortezomib 105Prednisone 102Irinotecan 100Dexamethasone 100

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Iodine-124 × Clear all
NCT03841617 2026-06-05

The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
30 enrolled
Head & Neck

Neoplasm Metastasis, Thyroid Neoplasms

NCT02152995 2026-04-13

Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
34 enrolled 18 charts
EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡